MPXV A29L inhibitors(Monkeypox antigen A29L inhibitors), MPXV A35R inhibitors(Monkeypox antigen A35R inhibitors), MPXV B6R inhibitors(Monkeypox antigen B6R inhibitors)

+ [1]

Therapeutic Areas

Infectious Diseases

Active Indication

Virus Diseases

Inactive Indication-

Originator Organization

Chinese PLA Academy of Military Medical Sciences

Active Organization

Chinese PLA Academy of Military Medical Sciences

Inactive Organization-

Drug Highest PhasePreclinical

First Approval Date-

Regulation-

100 Clinical Results associated with mRNA-A-LNP(Chinese PLA Academy of Military Medical Sciences)

100 Translational Medicine associated with mRNA-A-LNP(Chinese PLA Academy of Military Medical Sciences)

100 Patents (Medical) associated with mRNA-A-LNP(Chinese PLA Academy of Military Medical Sciences)

Literatures (Medical) associated with mRNA-A-LNP(Chinese PLA Academy of Military Medical Sciences)

28 Apr 2023·Signal transduction and targeted therapy

Monkeypox virus quadrivalent mRNA vaccine induces immune response and protects against vaccinia virus.

Article

Author: Cao, Yiming ; Huang, Weijin ; Wang, Xin ; Yang, Jing ; Sang, Ye ; Yu, Changxiao ; Lu, Haitao ; Fang, Jiaxin ; Liu, Fan ; Mai, Jierui ; Long, Jinrong ; Sun, Huisheng ; Miao, Yiqi ; Wang, Shengqi ; Zhang, Zhen ; Wang, Youchun

Monkeypox has been declared a public health emergency by the World Health Organization. There is an urgent need for efficient and safe vaccines against the monkeypox virus (MPXV) in response to the rapidly spreading monkeypox epidemic. In the age of COVID-19, mRNA vaccines have been highly successful and emerged as platforms enabling rapid development and large-scale preparation. Here, we develop two MPXV quadrivalent mRNA vaccines, named mRNA-A-LNP and mRNA-B-LNP, based on two intracellular mature virus specific proteins (A29L and M1R) and two extracellular enveloped virus specific proteins (A35R and B6R). By administering mRNA-A-LNP and mRNA-B-LNP intramuscularly twice, mice induce MPXV specific IgG antibodies and potent vaccinia virus (VACV) specific neutralizing antibodies. Further, it elicits efficient MPXV specific Th-1 biased cellular immunity, as well as durable effector memory T and germinal center B cell responses in mice. In addition, two doses of mRNA-A-LNP and mRNA-B-LNP are protective against the VACV challenge in mice. And, the passive transfer of sera from mRNA-A-LNP and mRNA-B-LNP-immunized mice protects nude mice against the VACV challenge. Overall, our results demonstrate that mRNA-A-LNP and mRNA-B-LNP appear to be safe and effective vaccine candidates against monkeypox epidemics, as well as against outbreaks caused by other orthopoxviruses, including the smallpox virus.

01 Mar 2021·Molecular TherapyQ1 · MEDICINE

Allergic Reactions and Anaphylaxis to LNP-Based COVID-19 Vaccines

Q1 · MEDICINE

Review

Author: Moghimi, S Moein

Mortality from coronavirus disease 2019 (COVID-19) in populations at high risk,such as the elderly, certain ethnic groups (e.g., Black/African American, and Hispanic/Latino persons), obese individuals, and those with endothelial dysfunction is substantial.While treatment options are limited, vaccination against SARS-CoV-2, the virus that causes COVID-19, is the most important global strategy in controlling the pandemic.Thus, two lipid nanoparticle (LNP)-based mRNA vaccines (Pfizer-Bio-NTech and Moderna) against SARS-CoV-2 have already received emergency use authorization by the US Food and Drug Administration (FDA).Anaphylaxis can occur after exposure to different allergens (e.g., food ingredients, venom, and drugs), but anaphylaxis after vaccination is rare and, in some vaccine recipients, not even related to the vaccine components.LNPs and other excipients are possible sources of allergens.

100 Deals associated with mRNA-A-LNP(Chinese PLA Academy of Military Medical Sciences)

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Virus Diseases	Preclinical	China	Chinese PLA Academy of Military Medical Sciences	28 Apr 2023

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

mRNA-A-LNP(Chinese PLA Academy of Military Medical Sciences)

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation